March 4, 2014
The latest on Vitamin K2: a new therapeutic agent for rheumatoid arthritis and for prostate cancer?
Vitamin K2, which is best known for its role in supporting bone health and its potential for countering osteoporosis, has also been investigated recently for other health benefits. A 2013 study reported that Vitamin K2 significantly decreased disease activity in patients with rheumatoid arthritis. And other research, also published in 2013, found evidence that Vitamin K2 is active in suppressing various types of prostate cancer cells. The authors of this study conclude that Vitamin K2 “may be a potential therapeutic agent in the treatment of prostate cancer.”
For further information about Vitamin K2, see the NYBC catalog entries for the Bone Up, Bone Up Ultra, and Vitamin K supplements (all from Jarrow):
Ebina, K, et al. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2013 Sep;23(5):1001-7. doi: 10.1007/s10165-012-0789-4.
Samykutty, A, et al. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med. 2013;2013:287358. doi: 10.1155/2013/287358.